MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 Amplification
Latest Information Update: 24 Apr 2025
At a glance
- Drugs Palbociclib (Primary)
- Indications Cancer; Lymphoma; Multiple myeloma
- Focus Therapeutic Use
- Acronyms MATCH - Subprotocol Z1C
Most Recent Events
- 10 Dec 2024 Planned End Date changed from 24 Mar 2025 to 31 Dec 2025.
- 03 May 2024 New trial record